Analyst Report: ZBH
1. EXECUTIVE SUMMARY
Zimmer Biomet rose 13.49% to $110.15 on Wednesday 4 November 2026 after third-quarter results beat estimates and management raised full-year guidance. Net sales of $2.063bn and adjusted EPS of $1.90 topped the $2.04bn and $1.88 estimates, according to the company's press release. The prior week had been weak, with Stryker's 30 October guidance cut raising fears of a hip and knee slowdown, and Zimmer's report was read as evidence against a broad orthopaedics downturn (MedTech Dive). Peers in health care equipment rose between 3.94% and 9.38% over the same session, so part of the gain follows the sector, while the earnings news explains the larger move. The shares closed at a 52-week high on volume of 3.07x the 50-session average. Knee sales fell 3.1%, and analysts disagree on whether that points to company execution or the market, which leaves the main open question for the next few quarters.
2. THE CATALYST
Zimmer reported before the open on 4 November (press release via Yahoo Finance). The figures:
| Item | Result | Estimate |
|---|---|---|
| Net sales | $2.063bn (+3.1% reported, +3.7% constant currency) | $2.04bn |
| Adjusted EPS | $1.90, flat year over year | $1.88 |
| Free cash flow | $372.4m | n/a |
The company raised its 2026 guidance (press release; MedTech Dive):
| Metric | New | Prior |
|---|---|---|
| Reported revenue growth | 4.4%–4.9% | 3.9%–4.9% |
| Organic constant-currency growth | 3.0%–3.5% | 2.25%–3.25% |
| Adjusted EPS | $8.50–$8.60 | $8.47–$8.59 |
Jefferies noted the organic growth range sits above consensus of 2.87% (Investing.com). Mix drew the most debate: hips grew about 6% to $536.5m, while knees fell 3.1% to $767.5m (press release). The shares opened at $105.90, traded between $101.35 and $112.55, and closed at $110.15, up from $97.06 the previous session. Only the 4 November session carried the news.
Analyst responses on the day (Investing.com):
- Stifel kept its Buy rating and raised its target to $125 from $110.
- Jefferies kept its Hold rating and raised its target to $120 from $105.
3. COMPANY PROFILE
Zimmer Biomet is a Healthcare sector medical device company with a $21.01bn market cap. It makes orthopaedic reconstructive products such as knee and hip implants, along with sports medicine, biologics, foot and ankle, upper extremity, trauma, craniomaxillofacial and thoracic products. Competitors named in the site's peer set include Stryker, Medtronic, Boston Scientific and Abbott, with Stryker the most direct orthopaedic rival.
The quarter's release also listed a multi-year extension of the limited exclusive distribution agreement with THINK Surgical, the Megalodon and SmartShot launches, and leadership promotions meant to speed US commercial work. Zimmer plans to file with the FDA for a surgical robot based on the Monogram acquisition, and expects a fully autonomous version to launch in the first half of 2027 (MedTech Dive). The stock trades at a forward P/E of 12.2 against a trailing 26.7 and yields 0.99%.
4. DEEP DIVE ANALYSIS
Do fundamentals justify the move? Revenue and EPS beat by small margins, so the guidance raise and the sector context carried most of the weight. The EPS range moved up by only $0.03 at the low end and $0.01 at the high end, while the organic growth range rose by 0.75 and 0.25 percentage points at the two ends. A 13.49% gain from those changes also reflects a stock that had been marked down on sector fears. The close sits 24.48% above the level of 7 October ($88.49), so the shares had already been recovering before the report.
Sector read-across. Stryker's guidance cut on 30 October attributed hip and knee softness to affordability and insurance pressure, and Zimmer fell 3.03% that day (MedTech Dive; facts). Zimmer's hip growth and raised outlook partly reversed that concern. ISRG (+9.38%) and SYK (+9.37%) also rose strongly on the session, while MDT, ABT and BSX gained between 5.33% and 6.15%. The S&P 500 rose 1.58%.
Knee debate. Management attributed the knee shortfall to commercial execution and a sales-force move to a fully dedicated model, and said it is not a market slowdown (MedTech Dive). J.P. Morgan's Robbie Marcus wrote that weakness across most knee players makes the shortfall more market-related. Knees are about 40% of sales per that note. The CEO's comments were also covered in a MassDevice headline that the brief did not open, and the call transcript was not reviewed.
Comparable episodes. Stifel's September 2025 target increase followed physician checks and pipeline progress, so it resembles this move only weakly. Stryker's October 2026 cut is the relevant comparison, and Zimmer's report undid part of that damage.
Bull case. Hips are growing, guidance rose, free cash flow was $372.4m, the robot programme gives a product catalyst in 2027, and the forward multiple of 12.2 remains low.
Bear case. Knees are 40% of sales and fell 3.1%. EPS was flat year over year. If the J.P. Morgan view proves right, the problem sits with the market and cannot be fixed by sales-force changes. The stock also closed below the $120 Jefferies target, which implies modest further upside.
5. TECHNICAL SNAPSHOT
The close of $110.15 is the highest in the table and sits just below the 52-week high of $112.55 set the same day, so no resistance level shows in the data. It stands above the 50-day average of $94.77 and the 200-day average of $91.44, and well above the 52-week low of $78.70. Volume of 6,169,900 was 3.07x the 50-session average of 2,008,010. The session low of $101.35 and the prior close of $97.06 are the nearest support levels; of the earlier closes in the table, $97.06 is the highest below the latest.
6. RISK FACTORS
- Knee sales fell 3.1%, and if the market-related view holds, the drop may continue.
- Adjusted EPS was flat year over year, so earnings growth relies on the guidance holding.
- The FDA filing for the Monogram robot has no date in the sources.
- The stock has gained 14.28% in five sessions and sits well above both moving averages, which leaves it exposed to a pullback.
- Further read-across from peers' results could move the shares. The brief found no confirmed next earnings date; the facts panel lists 4 November, which is the report just released.
- Two data points in the brief conflict with the facts: intraday headlines overstated the move, and the Jefferies note cites a 52-week high of $103.70 that the panel does not support. Neither is used here.
7. ACTIONABLE OUTLOOK
Short term (1-2 weeks): The shares trade at a 52-week high after a 3.07x volume session. Post-earnings drift and the Stifel and Jefferies target raises support the price, while the size of the one-day gain makes consolidation near $101 to $110 plausible (inference). A close back under $97.06 would erase the gain from the session.
Medium term (1-3 months): Direction depends on evidence about knees. Further commentary from peers on knee demand, and any dated FDA filing for the robot, would shape sentiment. Sell-side targets of $120 and $125 sit 8.9% and 13.5% above the close.
Long term: The thesis has improved modestly on the guidance raise and hip growth, with the knee question unresolved and the 2027 robot launch the main product catalyst. This is analysis only and not personal financial advice.